[{"id":"a9577f45-e57c-4142-84ae-067eccfe367a","acronym":"","url":"https://clinicaltrials.gov/study/NCT04007744","created_at":"2021-01-18T19:41:36.045Z","updated_at":"2024-07-02T16:35:12.692Z","phase":"Phase 1","brief_title":"Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT04007744","lead_sponsor":"Mayo Clinic","biomarkers":" EGFR • PD-L1 • BRAF • ALK • MSI • BCL2 • BCL2L11","pipe":" | ","alterations":" PD-L1 expression • MSI-H/dMMR","tags":["EGFR • PD-L1 • BRAF • ALK • MSI • BCL2 • BCL2L11"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Odomzo (sonidegib)"],"overall_status":"Recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 02/13/2020","start_date":" 02/13/2020","primary_txt":" Primary completion: 07/01/2024","primary_completion_date":" 07/01/2024","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2024-03-26"},{"id":"59c6f80d-6c97-43c5-b861-beaa6fc54bec","acronym":"MONAVI-1","url":"https://clinicaltrials.gov/study/NCT02591095","created_at":"2021-01-18T12:34:30.643Z","updated_at":"2024-07-02T16:37:01.571Z","phase":"Phase 2","brief_title":"A Study of ABT-263 as Single Agent in Women With Platinum Resistant/Refractory Recurrent Ovarian Cancer","source_id_and_acronym":"NCT02591095 - MONAVI-1","lead_sponsor":"Centre Francois Baclesse","biomarkers":" BCL2L11","pipe":"","alterations":" ","tags":["BCL2L11"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e navitoclax (ABT 263)"],"overall_status":"Completed","enrollment":" Enrollment 47","initiation":"Initiation: 01/01/2016","start_date":" 01/01/2016","primary_txt":" Primary completion: 04/01/2017","primary_completion_date":" 04/01/2017","study_txt":" Completion: 03/01/2019","study_completion_date":" 03/01/2019","last_update_posted":"2019-03-19"},{"id":"a3d4b8ea-48dd-4cdc-ae07-718e68da89e4","acronym":"","url":"https://clinicaltrials.gov/study/NCT02986919","created_at":"2021-01-18T14:41:37.538Z","updated_at":"2024-07-02T16:37:07.019Z","phase":"Phase 2","brief_title":"Study of CPI-0610 in Patients With Malignant Peripheral Nerve Sheath Tumors","source_id_and_acronym":"NCT02986919","lead_sponsor":"University of Texas Southwestern Medical Center","biomarkers":" BCL2L11","pipe":"","alterations":" ","tags":["BCL2L11"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pelabresib (DAK539)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 05/05/2017","start_date":" 05/05/2017","primary_txt":" Primary completion: 05/17/2018","primary_completion_date":" 05/17/2018","study_txt":" Completion: 05/17/2018","study_completion_date":" 05/17/2018","last_update_posted":"2018-09-11"}]